AU6906100A - Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis - Google Patents

Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis

Info

Publication number
AU6906100A
AU6906100A AU69061/00A AU6906100A AU6906100A AU 6906100 A AU6906100 A AU 6906100A AU 69061/00 A AU69061/00 A AU 69061/00A AU 6906100 A AU6906100 A AU 6906100A AU 6906100 A AU6906100 A AU 6906100A
Authority
AU
Australia
Prior art keywords
receptor
fusion protein
mediated uptake
protein inhibits
inhibits apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU69061/00A
Inventor
R. John Collier
Xiuhuai Liu
Richard J Youle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
National Institutes of Health NIH
Original Assignee
Harvard College
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, US Department of Health and Human Services filed Critical Harvard College
Publication of AU6906100A publication Critical patent/AU6906100A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU69061/00A 1999-08-16 2000-08-15 Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis Abandoned AU6906100A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14922099P 1999-08-16 1999-08-16
US60/149220 1999-08-16
PCT/US2000/022293 WO2001012661A2 (en) 1999-08-16 2000-08-15 RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS

Publications (1)

Publication Number Publication Date
AU6906100A true AU6906100A (en) 2001-03-13

Family

ID=22529285

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69061/00A Abandoned AU6906100A (en) 1999-08-16 2000-08-15 Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis

Country Status (2)

Country Link
AU (1) AU6906100A (en)
WO (1) WO2001012661A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022580A2 (en) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
SI1904104T1 (en) * 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
JP5114418B2 (en) * 2005-09-09 2013-01-09 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ Methods and compositions for inhibiting cell death or enhancing cell proliferation
US8221966B2 (en) 2006-03-31 2012-07-17 Dana Farber Cancer Institute Methods of determining cellular chemosensitivity
FR2988393B1 (en) * 2012-03-20 2014-05-09 Commissariat Energie Atomique INHIBITOR OF DIPHTERIC TOXIN-DOMAIN R-DERIVED HB-EGF FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HB-EGF / EGFR ENHANCEMENT
AU2013317985B2 (en) 2012-09-19 2019-06-13 Dana-Farber Cancer Institute, Inc. Dynamic BH3 profiling
AU2014323526B2 (en) 2013-09-19 2020-07-23 Dana-Farber Cancer Institute, Inc. Methods of BH3 profiling
CA2982928A1 (en) 2015-04-20 2016-10-27 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
EP3288964B1 (en) 2015-04-27 2024-02-21 Dana-Farber Cancer Institute, Inc. High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells
EP4086264B1 (en) 2015-05-18 2023-10-25 Sumitomo Pharma Oncology, Inc. Alvocidib prodrugs having increased bioavailability
AU2016301315C1 (en) 2015-08-03 2022-07-07 Sumitomo Pharma Oncology, Inc. Combination therapies for treatment of cancer
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
AU2017379847B2 (en) 2016-12-19 2022-05-26 Sumitomo Pharma Oncology, Inc. Profiling peptides and methods for sensitivity profiling
JP7196160B2 (en) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Treatment Regimens for Cancers Insensitive to BCL-2 Inhibitors Using the MCL-1 Inhibitor Albocidib
MX2021006544A (en) 2018-12-04 2021-07-07 Sumitomo Pharma Oncology Inc Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer.
JP2022525149A (en) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド Treatment of Acute Myeloid Leukemia (AML) with Venetoclax Failure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677274A (en) * 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
ATE321559T1 (en) * 1996-05-01 2006-04-15 Avant Immunotherapeutics Inc VACCINE BASED ON A PLASMID FOR THE TREATMENT OF ATHEROSCLEROSIS
US5856445A (en) * 1996-10-18 1999-01-05 Washington University Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities

Also Published As

Publication number Publication date
WO2001012661A3 (en) 2001-09-20
WO2001012661A2 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
AU5151100A (en) Extracellular signaling molecules
AU1434899A (en) Skin-compatible hand cleansers, particularly coarse hand cleansers
AU2610599A (en) N-terminally truncated glp-1 derivatives
AU4488200A (en) Modified protein matrices
AU6906100A (en) Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis
AU4409099A (en) Human transmembrane proteins
AU2557600A (en) Skin lightening agents
AU2001241100A1 (en) Polypeptide inducing apoptosis
AU4184299A (en) Human apoptosis associated proteins
AU2373800A (en) Neuron-associated proteins
AU5235699A (en) Sulfonamide derivatives
AU2575000A (en) Collagen-binding physiologically active polypeptide
AU3916400A (en) Human transmembrane proteins
AU2656799A (en) Metal-thiols as imminomodulating agents
AU4972100A (en) Current limiting composite material
AU1406001A (en) Auto-adhesive composition
AU5446499A (en) Apoptosis inducing agents
AU5619100A (en) Intracellular signaling molecules
AU5394300A (en) Tissue engineering
AU1705300A (en) Novel ultrasound contrast agents
AU5552700A (en) Chimeric proteins mediating targeted apoptosis
AU4352000A (en) Clasp-2 transmembrane proteins
AU7353500A (en) Apoptosis proteins
AU6983000A (en) Chimeric proteins
AU3543599A (en) Receptors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase